Company intelligence / Profile preview

Inside View Investments

Alameda, California, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

InSite Vision is a biotechnology company specializing in the development of topical therapies for ophthalmic diseases. The company is best known for its proprietary DuraSite drug delivery platform, which utilizes a synthetic polymer to extend the residence time of drugs on the eye's surface, thereby improving efficacy and patient compliance. Its commercial portfolio includes the marketed antibiotics AzaSite and Besivance, as well as the anti-inflammatory BromSite. In 2015, InSite Vision was acquired by Sun Pharmaceutical Industries to serve as a cornerstone for its global ophthalmic business.

Therapeutic areas: OphthalmologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Bausch + LombAkornSun Pharmaceutical Industries

Beyond the preview

Go deeper on Inside View Investments.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inside View Investments.

Explore the full profile